Fisher Asset Management LLC Has $11.03 Million Stake in Kiniksa Pharmaceuticals International, plc $KNSA

Fisher Asset Management LLC trimmed its position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 5.3% in the 4th quarter, Holdings Channel reports. The institutional investor owned 267,274 shares of the company’s stock after selling 15,014 shares during the period. Fisher Asset Management LLC’s holdings in Kiniksa Pharmaceuticals International were worth $11,025,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. GSA Capital Partners LLP lifted its holdings in Kiniksa Pharmaceuticals International by 281.9% in the 3rd quarter. GSA Capital Partners LLP now owns 77,984 shares of the company’s stock worth $3,028,000 after purchasing an additional 57,566 shares during the last quarter. Aberdeen Group plc acquired a new stake in Kiniksa Pharmaceuticals International in the 3rd quarter worth approximately $6,163,000. Essex Investment Management Co. LLC lifted its holdings in Kiniksa Pharmaceuticals International by 44.3% in the 3rd quarter. Essex Investment Management Co. LLC now owns 247,301 shares of the company’s stock worth $9,603,000 after purchasing an additional 75,864 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Kiniksa Pharmaceuticals International by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 3,112,937 shares of the company’s stock worth $128,409,000 after purchasing an additional 49,802 shares during the last quarter. Finally, SG Americas Securities LLC lifted its holdings in Kiniksa Pharmaceuticals International by 288.6% in the 4th quarter. SG Americas Securities LLC now owns 541,396 shares of the company’s stock worth $22,333,000 after purchasing an additional 402,078 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Stock Down 1.9%

Shares of NASDAQ KNSA opened at $51.84 on Thursday. The business’s 50 day moving average is $49.79 and its two-hundred day moving average is $45.26. The company has a market cap of $3.99 billion, a P/E ratio of 57.60 and a beta of 0.17. Kiniksa Pharmaceuticals International, plc has a 12 month low of $26.27 and a 12 month high of $59.87.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.18 by $0.09. The company had revenue of $214.27 million for the quarter, compared to the consensus estimate of $206.11 million. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The company’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.11 EPS. Sell-side analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.24 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Weiss Ratings upgraded Kiniksa Pharmaceuticals International from a “hold (c)” rating to a “hold (c+)” rating in a report on Wednesday, May 6th. Canaccord Genuity Group boosted their target price on Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Wedbush boosted their target price on Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the stock an “outperform” rating in a report on Wednesday, April 29th. Wells Fargo & Company boosted their target price on Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the stock an “overweight” rating in a report on Wednesday, April 29th. Finally, Jefferies Financial Group boosted their target price on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a report on Tuesday, April 28th. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $60.86.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals International news, COO Ross Moat sold 2,367 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $48.58, for a total value of $114,988.86. Following the transaction, the chief operating officer directly owned 12,029 shares of the company’s stock, valued at $584,368.82. The trade was a 16.44% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John F. Paolini sold 58,424 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $53.71, for a total value of $3,137,953.04. Following the completion of the transaction, the insider directly owned 65,623 shares in the company, valued at approximately $3,524,611.33. This represents a 47.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 653,301 shares of company stock worth $34,046,073. 51.98% of the stock is currently owned by company insiders.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.